Topoisomerase-i inhibitors in gynaecologic tumours
Verschraegen, C.F.; Kudelka, A.P.; Kavanagh, J.J.
Annals of the Academy of Medicine Singapore 27(5): 683-687
1998
ISSN/ISBN: 0304-4602 PMID: 9919340 Document Number: 485995
Topoisomerase inhibitors have been studied using various dose schedules in the treatment of refractory or recurrent gynaecologic cancers. Response rates are between 13% and 20%. Main toxic effects are haematologic and gastrointestinal. The latter remains problematic. Radiotherapy, alkylate, platinum analogs and topoisomerase II inhibitors are currently being studied in combination with camptothecins.